The immunomodulatory effect of probiotics beyond atopy: An update

Journal of Asthma

Volumn 51, Issue 3, 2014, Pages 320-332

  Vitaliti, Giovanna ^a   Pavone, Piero ^a   Guglielmo, Francesco ^a   Spataro, Giuseppina ^a   Falsaperla, Raffaele ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Alternative medicine; Immunopathogenesis; Paediatrics; Pharmacotherapy; Prevention

Indexed keywords

PROBIOTIC AGENT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; ATOPY; BIFIDOBACTERIUM; CHILDHOOD DISEASE; DRUG MECHANISM; HELMINTH; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOREGULATION; INFLAMMATORY BOWEL DISEASE; INTESTINE; INTESTINE LYMPHATIC TISSUE; LACTOBACILLUS; MEDLINE; META ANALYSIS; MILK ALLERGY; MYCOBACTERIUM; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SAPROTROPH; SYSTEMATIC REVIEW;

ANIMALS; ARTHRITIS, RHEUMATOID; ASTHMA; BIFIDOBACTERIUM; CATTLE; COMPLEMENTARY THERAPIES; GASTROINTESTINAL TRACT; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNE SYSTEM DISEASES; IMMUNOMODULATION; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; LACTOBACILLUS; MILK HYPERSENSITIVITY; PROBIOTICS;

EID: 84898943285     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2013.862259     Document Type: Article

References (131)

1. Burke W, Fesinmeyer M, Reed K, Hampson L, Carlsten C. Familyhistory as a predictor of asthma risk. Am J Prev Med 2003;24:160-169.
2. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989;299:1259-1260.
3. Ouwehand AC. Antiallergic effect of probiotics. J Nutr 2007;137:794S-797S.
4. Moore WEC, Holdeman LV. Human fecal flora: the normal floraof 20 Japanese-Hawaiians. Appl Microbiol 2007;27:961-979.
5. Macpherson AJ, Geuking MB, McCoy KD. Immune responsesthat adapt the intestinal mucosa to commensal intestinal bacteria.Immunology 2005;115:153-162.
6. Mazmanian SK, Kasper DL. The love-hate relationship betweenbacterial polysaccharides and the host immune system. Nat RevImmunol 2005;6:849-858.
7. Baba N, Samson S, Bourdet-Sicard R, Rubio M, Sarfati M. Selectedcommensal-related bacteria and Toll-like receptor 3 agonist combinatorialcodes synergistically induce interleukin-12 production bydendritic cells to trigger a T helper type 1 polarizing programme.Immunology 2009;128:e523-e531.
8. Rescigno M, Urbano M, Valzasina B, Francolini M, Rotta G,Bonasio R, Granucci F, et al. Dendritic cells express tight junctionproteins and penetrate gut epithelial monolayers to sample bacteria.Nat Immunol 2001;2:361-367.
9. Lee J, Mo JH, Shen C, Rucker AN, Raz E. Toll-like receptorsignaling in intestinal epithelial cells contributes to colonichomoeostasis. Curr Opin Gastroenterol 2007;23:27-31.
10. Rakoff-Nahoum S, Hao L, Medzhitov R. Role of toll-like receptorsin spontaneous commensal-dependent colitis. Immunity 2006;25:319-329.
11. Trinchieri G, Sher A. Cooperation of toll-like receptor signals ininnate immune defence. Nat Rev Immunol 2007;7:179-190.
12. Cario E. Bacterial interactions with cells of the intestinal mucosa:toll-like receptors and NOD2. Gut 2005;54:1182-1193.
13. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendriticcells. Annu Rev Immunol 2003;21:685-711.
14. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM.Th17: an effector CD4 T cell lineage with regulatory T cell ties.Immunity 2006;24:677-688.
15. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M,Weiner HL, Kuchroo VK. Reciprocal developmental pathways forthe generation of pathogenic effector Th17 and regulatory T cells.Nature 2006;441:235-238.
16. Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E,Oukka M, Kuchroo VK, Hafler DA. IL-21 and TGF-beta arerequired for differentiation of human T(H)17 cells. Nature 2008;454:350-352.
17. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia SF. Interleukins1beta and 6 but not transforming growth factor-beta are essentialfor the differentiation of interleukin 17-producing human T helpercells. Nat Immunol 2007;8:942-949.
18. Rimoldi M, Chieppa M, Larghi P, Vulcano M, Allavena P, RescignoM. Monocyte-derived dendritic cells activated by bacteria or bybacteria-stimulated epithelial cells are functionally different. Blood2005;106:2818-2826.
19. Hoarau C, Lagaraine C, Martin L, Velge-Roussel F, Lebranchu Y.Supernatant of Bifidobacterium breve induces dendritic cellmaturation, activation, and survival through a toll-like receptor 2pathway. J Allergy Clin Immunol 2006;117:696-702.
20. Gad M, Ravn P, Søborg DA, Ouwehand AC, Jensen SS. Regulationof the IL-10/IL-12 axis in human dendritic cells with probioticbacteria. FEMS Immunol Med Microbiol 2011;63:93-107.
21. Baba N, Samson S, Bourdet-Sicard R, Rubio M, Sarfati M.Commensal bacteria trigger a full dendritic cell maturation programthat promotes the expansion of non-Tr1 suppressor T cells. J LeukocBiol 2008;84:468-476.
22. Smits HH, van Beelen AJ, Hessle C, Westland R, de Jong E,Soeteman E, Wold A, et al. Commensal gram-negative bacteriaprime human dendritic cells for enhanced IL-23 and IL-27expression and enhanced Th1 development. Eur J Immunol 2004;34:1371-1380.
23. Rescigno M. Mucosal immunology and bacterial handling in theintestine. Best Pract Res Clin Gastroenterol 2013;27:17-24.
24. Niess JH, Brand S, Gu X, Landsman L, Jung S, McCormick BA,Vyas JM, et al. CX3CR1-mediated dendritic cell access tothe intestinal lumen and bacterial clearance. Science 2005;307:254-258.
25. Rescigno M. The intestinal epithelial barrier in the control ofhomeostasis and immunity. Trends Immunol 2011;32:256-264.
26. Wells JM, Rossi O, Meijerink M, van Baarlen P. Epithelial crosstalkat the microbiota-mucosal interface. Proc Natl Acad Sci USA 2011;108:4607-4614.
27. Yin Y, Wang Y, Zhu L, Liu W, Liao N, Jiang M, Zhu B, et al.Comparative analysis of the distribution of segmented filamentousbacteria in humans, mice and chickens. ISME J 2013;7:615-621.
28. Iliev ID, Spadoni I, Mileti E, Matteoli G, Sonzogni A, SampietroGM, Foschi D, et al. Human intestinal epithelial cells promote thedifferentiation of tolerogenic dendritic cells. Gut 2009;58:1481-1489.
29. Jaensson E, Uronen-Hansson H, Pabst O, Eksteen B, Tian J,Coombes JL, Berg PL, et al. Small intestinal CD103\+ dendriticcells display unique functional properties that are conservedbetween mice and humans. J Exp Med 2008;205:2139-2149.
30. Diehl GE, Longman RS, Zhang JX, Breart B, Galan C, Cuesta A,Schwab SR, Littman DR. Microbiota restricts trafficking ofbacteria to mesenteric lymph nodes by CX(3)CR1(hi) cells.Nature 2013;494:116-120.
31. Hadis U, Wahl B, Schulz O, Hardtke-Wolenski M, Schippers A,Wagner N, Müller W, et al. Intestinal tolerance requires gut homingand expansion of FoxP3\+ regulatory T cells in the lamina propria.Immunity 2011;34:237-246.
32. Kayama H, Ueda Y, Sawa Y, Jeon SG, Ma JS, Okumura R, Kubo A,et al. Intestinal CX3C chemokine receptor 1(high) (CX3CR1(high))myeloid cells prevent T-cell-dependent colitis. Proc Natl Acad SciUSA 2012;109:5010-5015.
33. Schulz O, Jaensson E, Persson EK, Liu X, Worbs T, Agace WW,Pabst O. Intestinal CD103\+, but not CX3CR1\+, antigen samplingcells migrate in lymph and serve classical dendritic cell functions. J Exp Med 2009;206:3101-3114.
34. Medina-Contreras O, Geem D, Laur O, Williams IR, Lira SA,Nusrat A, Parkos CA, Denning TL. CX3CR1 regulates intestinalmacrophage homeostasis, bacterial translocation, andcolitogenic Th17 responses in mice. J Clin Invest 2011;121:4787-4795.
35. Smythies LE, Sellers M, Clements RH, Mosteller-Barnum M,Meng G, Benjamin WH, Orenstein JM, Smith PD. Human intestinalmacrophages display profound inflammatory anergy despite avidphagocytic and bacteriocidal activity. J Clin Invest 2005;115:66-75.
36. Salazar-Gonzalez RM, Niess JH, Zammit DJ, Ravindran R,Srinivasan A, Maxwell JR, Stoklasek T, et al. CCR6-mediateddendritic cell activation of pathogen-specific T cells in Peyer'spatches. Immunity 2006;24:623-632.
37. Iwasaki A, Kelsall BL. Localization of distinct Peyer's patchdendritic cell subsets and their recruitment by chemokines macrophageinflammatory protein (MIP)-3alpha, MIP-3beta, and secondarylymphoid organ chemokine. J Exp Med 2000;191:1381-1394.
38. Fink LN, Frokiaer H. Dendritic cells from Peyer's patches andmesenteric lymph nodes differ from spleen dendritic cells in theirresponse to commensal gut bacteria. Scand J Immunol 2008;68:270-279.
39. Contractor N, Louten J, Kim L, Biron CA, Kelsall BL.Cutting edge: Peyer's patch plasmacytoid dendritic cells (pDCs)produce low levels of type I interferons: possible role for IL-10,TGFbeta, and prostaglandin E2 in conditioning a unique mucosalpDC phenotype. J Immunol 2007;179:2690-2694.
40. Macpherson AJ, Uhr T. Induction of protective IgA by intestinaldendritic cells carrying commensal bacteria. Science 2004;303:1662-1665.
41. Mowat AM. Anatomical basis of tolerance and immunity tointestinal antigens. Nat Rev Immunol 2003;3:331-341.
42. Morelli L, Capurso L. FAO/WHO guidelines on probiotics:10 years later. J Clin Gastroenterol 2012;46:S1-S2.
43. Alvarez-Olmos MI, Oberhelman RA. Probiotic agents and infectiousdiseases: a modern perspective on a traditional therapy. Clin Infect Dis 2001;32:1567-1576.
44. Yazdanbakhsh M, Kremsner PG, van Ree R. Allergy, parasites, andthe hygiene hypothesis. Science 2002;96:490-494.
45. Rautava S, Kalliomaki M, Isolauri E. New therapeutic strategy forcombating the increasing burden of allergic disease: probiotics-aNutrition, Allergy, Mucosal Immunology and Intestinal Microbiota(NAMI) Research Group report. J Allergy Clin Immunol 2005;116:31-37.
46. Rook GA, Brunet LR. Old friends for breakfast. Clin Exp Allergy2005;35:841-842.
47. von der Weid T, Bulliard C, Schiffrin EJ. Induction by a lactic acidbacterium of a population of CD4(\+) T cells with low proliferativecapacity that produce transforming growth factor beta andinterleukin-10. Clin Diagn Lab Immunol 2001;8:695-701.
48. Smits HH, Engering A, van der Kleij D, de Jong EC, Schipper K,van Capel TM, Zaat BA, et al. Selective probiotic bacteria induceIL-10-producing regulatory T cells in vitro by modulating dendriticcell function through dendritic cell-specific intercellular adhesionmolecule 3-grabbing nonintegrin. J Allergy Clin Immunol 2005;115:1260-1267.
49. Lammers KM, Brigidi P, Vitali B, Gionchetti P, Rizzello F,Caramelli E, Matteuzzi D, Campieri M. Immunomodulatory effectsof probiotic bacteria DNA: IL-1 and IL-10 response in humanperipheral blood mononuclear cells. FEMS Immunol MedMicrobiol 2003;8:165-172.
50. Guarner F. Enteric flora in health and disease. Digestion 2006;73:5-12.
51. Rook GA, Brunet LR. Microbes, immunoregulation, and the gut. Gut 2005;54:317-320.
52. Romagnani S. The increased prevalence of allergy and the hygienehypothesis: missing immune deviation, reduced immune suppression,or both? Immunology 2004;112:352-363.
53. Rautava S, Ruuskanen O, Ouwehand A, Salminen S, Isolauri E.The hygiene hypothesis of atopic disease-an extended version. J Pediatr Gastroenterol Nutr 2004;38:378-388.
54. Noverr MC, Noggle RM, Toews GB, Huffnagle GB. Role ofantibiotics and fungal microbiota in driving pulmonary allergicresponses. Infect Immun 2004;72:4996-5003.
55. Forsythe P, Inman MD, Bienenstock J. Oral treatment with liveLactobacillus reuteri inhibits the allergic airway response in mice. Am J Respir Crit Care Med 2007;175:561-569.
56. Noverr MC, Falkowski NR, McDonald RA, McKenzie AN,Huffnagle GB. Development of allergic airway disease in micefollowing antibiotic therapy and fungal microbiota increase: role ofhost genetics, antigen, and interleukin-13. Infect Immun 2005;73:30-38.
57. Prescott SL, Dunstan JA, Hale J, Breckler L, Lehmann H, WestonS, Richmond P. Clinical effects of probiotics are associated withincreased interferon-gamma responses in very young children withatopic dermatitis. Clin Exp Allergy 2005;35:1557-1564.
58. Vitaliti G, Cimino C, Coco A, Pratico AD, Lionetti E. Theimmunopathogenesis of cow's milk protein allergy (CMPA).Ital J Pediatr 2012;23:35.
59. Lara-Villoslada F, Sierra S, D́az-Ropero MP, Rodŕguez JM,Xaus J, Olivares M. Safety assessment of Lactobacillus fermentumCECT5716, a probiotic strain isolated from human milk. J DairyRes 2009;76:216-221.
60. Salazar N, Ruas-Madiedo P, Kolida S, Collins M, Rastall R, GibsonG, de Los Reyes-Gavilán CG. Exopolysaccharides produced byBifidobacterium longum IPLA E44 and Bifidobacterium animalissubsp. lactis IPLA R1 modify the composition and metabolicactivity of human faecal microbiota in pH-controlled batch cultures. Int J Food Microbiol 2009;135:260-267.
61. Conover MS, Sloan GP, Love CF, Sukumar N, Deora R. The Bpspolysaccharide of Bordetella pertussis promotes colonizationand biofilm formation in the nose by functioning as an adhesin. Mol Microbiol 2010;77:1439-1455.
62. Xu CL, Wang YZ, Jin ML, Yang XQ. Preparation, characterizationand immunomodulatory activity of selenium-enriched exopolysaccharideproduced by bacterium Enterobacter cloacae Z0206.Bioresour Technol 2009;100:2095-2097.
63. Alp G, Aslim B. Relationship between the resistance to bilesalts and low pH with exopolysaccharide (EPS) production ofBifidobacterium spp. isolated from infants feces and breast milk.Anaerobe 2010;16:101-105.
64. Fanning S, Hall LJ, Cronin M, Zomer A, MacSharry J, Goulding D,Motherway MO, et al. Bifidobacterial surface-exopolysaccharidefacilitates commensal-host interaction through immune modulationand pathogen protection. Proc Natl Acad Sci 2012;109:2108-2113.
65. Weintraub A. Immunology of bacterial polysaccharide antigens.Carbohydr Res 2003;338:2539-2547.
66. Buchanan RM, Arulanandam BP, Metzger DW. IL-12 enhancesantibody responses to T-independent polysaccharide vaccines in theabsence of T and NK cells. J Immunol 1998;161:5525-5533.
67. Moussu H, Van Overtvelt L, Horiot S, Tourdot S, Airouche S,Zuercher A, Holvoet S, et al. Bifidobacterium bifidum NCC 453promotes tolerance induction in murine models of sublingualimmunotherapy. Int Arch Allergy Immunol 2012;158:35-42.
68. López P, González-Rodŕguez I, Sánchez B, Gueimonde M,Margolles A, Suárez A. Treg-inducing membrane vesicles fromBifidobacterium bifidum LMG13195 as potential adjuvants inimmunotherapy. Vaccine 2012;30:825-829.
69. Foligné B, Dewulf J, Breton J, Claisse O, Lonvaud-Funel A, Pot B.Probiotic properties of non-conventional lactic acid bacteria:immunomodulation by Oenococcus oeni. Int J Food Microbiol2010;140:136-145.
70. Sepp E, Julge K, Mikelsaar M, Björkstén B. Intestinal microbiotaand immunoglobulin E responses in 5-year-old Estonian children.Clin Exp Allergy 2005;35:1141-1146.
71. Kalliomäki M, Kirjavainen P, Eerola E, Kero P, Salminen S,Isolauri E. Distinct patterns of neonatal gut microflora in infantsdeveloping or not developing atopy. J Allergy Clin Immunol 2001;107:129.
72. Ouwehand AC, Isolauri E, He F, Hashimoto H, Benno Y,Salminen S. Differences in Bifidobacterium flora compositionin allergic and healthy infants. J Allergy Clin Immunol 2001;108:144-145.
73. Murray CS, Tannock GW, Simon MA, Harmsen HJ, Welling GW,Custovic A, Woodcock A. Fecal microbiota in sensitized wheezyand non-sensitized non-wheezy children: a nested case-controlstudy. Clin Exp Allergy 2005;35:741-745.
74. He F, Morita H, Hashimoto H, Kurisaki J-I, Hosoda M, Kurisaki J,Ouwehand AC, et al. Intestinal Bifidobacterium species inducevarying cytokine production. J Allergy Clin Immunol 2002;109:1035-1036.
75. Morita H, He F, Fuse T, Ouwehand AC, Hashimoto H, Hosoda M,Mizumachi K, Kurisaki J. Adhesion of lactic acid bacteria toCaco-2 cells and their effect on cytokine secretion. MicrobiolImmunol 2002;46:293-297.
76. He F, Ouwehand AC, Isolauri E, Hashimoto H, Benno Y,Salminen S. Comparison of mucosal adhesion and speciesidentification of bifidobacteria isolated from healthy and allergicinfants. FEMS Immunol Med Microbiol 2001;30:43-47.
77. Norin E, Midtvedt T, Björksten B. Development of faecal shortchainfatty acid pattern during the first year of life in Estonian andSwedish infants. Microb Ecol Health Dis 2004;16:8-12.
78. Zeiger RS. Food allergen avoidance in the prevention of foodallergy in infants and children. Pediatrics 2003;111:1662-1671.
79. Isolauri E, Arvola T, Sütas Y, Moilanen E, Salminen S. Probioticsin the management of atopic eczema. Clin Exp Allergy 2000;30:1604-1610.
80. Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, JeppesenDL, Valerius NH, Paerregaard A. Effect of probiotic Lactobacillusstrains in children with atopic dermatitis. J Allergy Clin Immunol2003;111:389-395.
81. Vitaliti G, Pavone P, Guglielmo F, Falsaperla R. Sublingualimmunotherapy in preschool children: an update. Expert Rev ClinImmunol 2013;9:385-390.
82. Sampson HA. Update on food allergy. J Allergy Clin Immunol2004;113:805- 820.
83. Host A. Cow's milk protein allergy and intolerance in infancy.Some clinical, epidemiological and immunological aspects.Pediatr Allergy Immunol 1994;5:1-36.
84. James JM, Sampson HA. Immunologic changes associated withthe development of tolerance in children with cow milk allergy. J Pediatr 1992;121:371-377.
85. Host A, Halken S, Jacobsen HP, Christensen AE, Herskind AM,Plesner K. Clinical course of cow's milk protein allergy/intoleranceand atopic diseases in childhood. Pediatr Allergy Immunol2002;13:23-28.
86. Strobel S. Neonatal oral tolerance. Ann N Y Acad Sci 1996;778:88-102.
87. Bjorksten B, Naaber P, Sepp E, Mikelsaar M. The intestinalmicroflora in allergic Estonian and Swedish 2-year-old children.Clin Exp Allergy 1999;29:342-346.
88. Pessi T, Sutas Y, Marttinen A, Isolauri E. Probiotics reinforcemucosal degradation of antigens in rats: implications for therapeuticuse of probiotics. J Nutr 1998;128:2313-2318.
89. Brouwer ML, Wolt-Plompen SA, Dubois AE, van der Heide S,Jansen DF, Hoijer MA, Kauffman HF, Duiverman EJ. No effectsof probiotics on atopic dermatitis in infancy: a randomizedplacebo-controlled trial. Clin Exp Allergy 2006;36:899-906.
90. Vandenplas Y, Veereman-Wauters G, De Greef E, Peeters S,Casteels A, Mahler T, Devreker T, Hauser B. Probiotics andprebiotics in prevention and treatment of diseases in infants andchildren. J Pediatr (Rio J) 2011;87:292-300.
91. Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, JeppesenDL, Valerius NH, Paerregaard A. Effect of probiotic Lactobacillusstrains in children with atopic dermatitis. J Allergy Clin Immunol2003;111:389-395.
92. Sistek D, Kelly R, Wickens K, Stanley T, Stanley T, Fitzharris P,Crane J. Is the effect of probiotics on atopic dermatitis confinedto food sensitized children? Clin Exp Allergy 2006;36:629-633.
93. Viljanen M, Pohjavuori E, Haahtela T, Korpela R, Kuitunen M,Sarnesto A, Vaarala O, Savilahti E. Induction of inflammationas a possible mechanism of probiotic effect in atopic eczemadermatitissyndrome. J Allergy Clin Immunol 2005;115:1254-1259.
94. Weston S, Halbert A, Richmond P, Prescott SL. Effects ofprobiotics on atopic dermatitis: a randomised controlled trial.Arch Dis Child 2005;90:892-897.
95. Wang MF, Lin HC, Wang YY, Hsu CH. Treatment of perennialallergic rhinitis with lactic acid bacteria. Pediatr Allergy Immunol2004;15:152-158.
96. Majamaa H, Isolauri E. Probiotics: a novel approach in themanagement of food allergy. J Allergy Clin Immunol 1997;99:179-185.
97. Viljanen M, Kuitunen M, Haahtela T, Juntunen-Backman K,Korpela R, Savilahti E. Probiotic effects on faecal inflammatorymarkers and on faecal IgA in food allergic atopic eczema/dermatitis syndrome infants. Pediatr Allergy Immunol 2005;16:65-71.
98. Viljanen M, Savilahti E, Haahtela T, Juntunen-Backman K,Korpela R, Poussa T, Tuure T, Kuitunen M. Probiotics in thetreatment of atopic eczema/dermatitis syndrome in infants: adouble-blind placebo-controlled trial. Allergy 2005;60:494-500.
99. Berni Canani R Nocerino R Terrin G Coruzzo A Cosenza L Leone L Troncone R. Effect of Lactobacillus GG on toleranceacquisition in infants with cow's milk allergy: a randomized trial. J Allergy Clin Immunol.2012. 129. 580-582.
100. Ghadimi D, Folster-Holst R, de Vrese M, Winkler P, Heller KJ,Schrezenmeir J. Effects of probiotic bacteria and their genomicDNA on TH1/TH2-cytokine production by peripheral bloodmononuclear cells (PBMCs) of healthy and allergic subjects.Immunobiology 2008; 213:677-692.
101. Pohjavuori E, Viljanen M, Korpela R, Kuitunen M, Tiittanen M,Vaarala O, Savilahti E. Lactobacillus GG effect in increasingIFN-gamma production in infants with cow's milk allergy. J Allergy Clin Immunol 2004;114:131-136.
102. Donato KA, Gareau MG, Wang YJ, Sherman PM. Lactobacillusrhamnosus GG attenuates interferon-g and tumour necrosis factoralpha-induced barrier dysfunction and pro-inflammatory signalling.Microbiology 2010;156:3288-3297.
103. Mileti E, Matteoli G, Iliev ID, Rescigno M. Comparison of theimmunomodulatory properties of three probiotic strainsof lactobacilli using complex culture systems: prediction forin vivo efficacy. PLoS One 2009;4:e7056.
104. Nagler-Anderson C. Tolerance and immunity in the intestinalimmune system. Crit Rev Immunol 2000;20:103-120.
105. Newberry RD, Stevenson WF, Lorenz RG. Cycloxynegase-2-dependent arachidonic acid metabolites are essential modulatorsof the immune response to dietary antigen. Nat Med 1999;5:900-906.
106. Sudo N, Sawamura S, Tanaka K, Aiba Y, Kubo C, Koga Y.The requirement of intestinal bacterial flora for the developmentof an IgE production system fully susceptible to oral toleranceinduction. J Immunol 1997;159:1739-1745.
107. Calder PC, Albers R, Antoine JM, Blum S, Bourdet-Sicard R,Ferns GA, Folkerts G, et al. Inflammatory disease processes andinteractions with nutrition. Br J Nutr 2009;101:S1-S45.
108. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S,Talbot IC, Nicholls RJ, et al. Once daily high dose probiotictherapy (VSL#3) for maintaining remission in recurrent orrefractory pouchitis. Gut 2004;53:108-114.
109. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M.Effect of Lactobacillus rhamnosus GG on ileal pouch inflammationand microbial flora. Aliment Pharmacol Ther 2003;17:509-515.
110. Gupta P, Andrew H, Kirschner BS, Guandalini S. Is LactobacillusGG helpful in children with Crohn's disease? Results of apreliminary, open-label study. J Pediatr Gastroenterol Nutr 2000;31:453-457.
111. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA,Rath HC. Lactobacillus GG in inducing and maintaining remissionof Crohn's disease. BMC Gastroenterol 2004;15:4-5.
112. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C.Ineffectiveness of probiotics in preventing recurrence aftercurative resection for Crohn's disease: a randomised controlledtrial with Lactobacillus GG. Gut 2002;51:405-409.
113. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D,Bazzocchi G, Poggioli G, et al. Oral bacteriotherapy as maintenancetreatment in patients with chronic pouchitis: a double-blind,placebo-controlled trial. Gastroenterology 2000;119:305-309.
114. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME,Gigliobianco A. Low-dose balsalazide plus a high-potencyprobiotic preparation is more effective than balsalazide alone ormesalazine in the treatment of acute mild-to-moderate ulcerativecolitis. Med Sci Monit 2004;10:I126-I131.
115. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC,Candelli M, Novi M, et al. Efficacy of Lactobacillus GG inmaintaining remission of ulcerative colitis. Aliment PharmacolTher 2006;23:1567-1574.
116. Cui HH, Chen CL, Wang JD, Yang YJ, Cun Y, Wu JB, Liu YH,et al. Effects of probiotic on intestinal mucosa of patients withulcerative colitis. World J Gastroenterol 2004;10:1521-1525.
117. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A,Otani T. Randomized controlled trial of the effect ofbifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003;22:56-63.
118. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV,O'neil DA, Macfarlane GT. Synbiotic therapy (Bifidobacteriumlongum/Synergy 1) initiates resolution of inflammation in patientswith active ulcerative colitis: a randomised controlled pilot trial. Gut 2005;54:242-249.
119. Nowak B, Ciszek-Lenda M, Sróttek M, Gamian A, Kontny E,Górska-Fra?czek S, Marcinkiewicz J. Lactobacillus rhamnosusexopolysaccharide ameliorates arthritis induced by the systemicinjection of collagen and lipopolysaccharide in DBA/1 mice.Arch Immunol Ther Exp (Warsz) 2012;60:211-220.
120. So JS, Song MK, Kwon HK, Lee CG, Chae CS, Sahoo A, Jash A,et al. Lactobacillus casei enhances type II collagen/glucosaminemediatedsuppression of inflammatory responses in experimentalosteoarthritis. Life Sci 2011;14(88):358-366.
121. Amdekar S, Singh V, Singh R, Sharma P, Keshav P, Kumar A.Lactobacillus casei reduces the inflammatory joint damageassociated with collagen-induced arthritis (CIA) by reducing thepro-inflammatory cytokines: Lactobacillus casei: COX-2 inhibitor. J Clin Immunol 2011;31:147-154.
122. Feleszko W, Jaworska J, Rha RD, Steinhausen S, Avagyan A,Jaudszus A, Ahrens B, et al. Probiotic-induced suppressionof allergic sensitization and airway inflammation is associatedwith an increase of T regulatory-dependent mechanisms in amurine model of asthma. Clin Exp Allergy 2007;37:498-505.
123. Hong HJ, Kim E, Cho D, Kim TS. Differential suppression ofheat-killed lactobacilli isolated from kimchi, a Korean traditionalfood, on airway hyper-responsiveness in mice. J Clin Immunol2010;30:449-458.
124. Yu J, Jang SO, Kim BJ, Song YH, Kwon JW, Kang MJ, Choi WA,et al. The effects of Lactobacillus rhamnosus on the prevention ofasthma in a murine model. Allergy Asthma Immunol Res 2010;2:199-205.
125. Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P,Isolauri E. Probiotics in primary prevention of atopic disease: arandomised placebo-controlled trial. Lancet 2001;357:1076-1079.
126. Helin T, Haahtela S, Haahtela T. No effect of oral treatment withan intestinal bacterial strain, Lactobacillus rhamnosus (ATCC53103), on birch-pollen allergy: a placebo-controlled double-blindstudy. Allergy 2002;57:243-246.
127. Shida K, Takahashi R, Iwadate E, Takamizawa K, Yasui H, Sato T,Habu S, et al. Lactobacillus casei strain Shirota suppresses serumimmunoglobulin E and immunoglobulin G1 responses andsystemic anaphylaxis in a food allergy model. Clin Exp Allergy2002;32:563-570.
128. Pavone P, Longo MR, Taibi R, Nunnari G, Romano C, Passaniti E,Falsaperla R. Acute asthma in children: treatment in emergency.Eur Rev Med Pharmacol Sci 2011;15:711-716.
129. Pavone P, Longo MR, Scalia F, Polosa R, Kira J, Falsaperla R.Recurrent Hopkin's syndrome: a case report and review of theliterature. J Neurol Sci 2010;297:89-91.
130. Pochard P, Gosset P, Grangette C, Andre C, Tonnel AB, Pestel J,Mercenier A. Lactic acid bacteria inhibit Th2 cytokine productionby mononuclear cells from allergic patients. J Allergy ClinImmunol 2002;110:617-623.
131. Jang SO, Kim HJ, Kim YJ, Kang MJ, Kwon JW, Seo JH, Kim HY,et al. Asthma prevention by Lactobacillus rhamnosus in a mousemodel is associated with CD4(\+)CD25(\+)FoxP3(\+) T Cells.Allergy Asthma Immunol Res 2012;4 150-156